As virtually all of you are aware, Mohit Khera, MD, Director for Andrology Research at Baylor College of Medicine, last year published a study demonstrating that finasteride can damage the normal functioning of 3,764 human genes.
As virtually all of you are unaware, however, Roberto Cosimo Melcangi, PhD, Head of the Neuroendocrinology Unit in the Department of Pharmacological and Biomolecular Sciences at the University of Milano (UniMi), recently wrapped up research that identified, via a next-generation sequencing technology known as RNA-seq, several genes that are likely responsible for the side effects observed in PFS patients.
That’s big news. And you needn’t be an MD or PhD to figure out that, from here, the path to mapping the precise molecular nature of finasteride-induced sexual dysfunction promises to be much shorter than anyone anticipated. Ditto the path to exploring potential therapies for this and other persistent side effects that have been the ruin of many thousands of men worldwide, with no signs of slowing down.
Just one small hitch: Prof. Melcangi’s new research represents Phase I of a two-phase project. Phase II, which requires new funding, necessitates:
(a) Analyzing the raw data from Phase I,
(b) writing a formal study based on that analysis, and
(c) publishing that study in a high-impact-factor, peer-reviewed medical journal.